Advertisement
BLFS vs LAB
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BLFS is a StrongBuy and LAB is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BLFS’s FA Score shows that 1 FA rating(s) are green whileLAB’s FA Score has 0 green FA rating(s).
- BLFS’s FA Score: 1 green, 4 red.
- LAB’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BLFS’s TA Score shows that 5 TA indicator(s) are bullish while LAB’s TA Score has 4 bullish TA indicator(s).
- BLFS’s TA Score: 5 bullish, 5 bearish.
- LAB’s TA Score: 4 bullish, 4 bearish.
Price Growth
BLFS (@Pharmaceuticals: Other) experienced а -1.53% price change this week, while LAB (@Medical/Nursing Services) price change was +0.78% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.09%. For the same industry, the average monthly price growth was +6.96%, and the average quarterly price growth was +33.57%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.08%. For the same industry, the average monthly price growth was +1.73%, and the average quarterly price growth was +23.90%.
Reported Earning Dates
BLFS is expected to report earnings on Nov 06, 2025.
LAB is expected to report earnings on Nov 11, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (-2.09% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-0.08% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| BLFS | LAB | BLFS / LAB | |
| Capitalization | 1.2B | 493M | 244% |
| EBITDA | 17.4M | -120.98M | -14% |
| Gain YTD | -3.544 | -26.286 | 13% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 93.5M | 172M | 54% |
| Total Cash | 81.8M | 237M | 35% |
| Total Debt | 23.8M | 28.6M | 83% |
BLFS | LAB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 8 | 74 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 34 Fair valued | |
PROFIT vs RISK RATING 1..100 | 91 | 100 | |
SMR RATING 1..100 | 92 | 96 | |
PRICE GROWTH RATING 1..100 | 46 | 60 | |
P/E GROWTH RATING 1..100 | 13 | 100 | |
SEASONALITY SCORE 1..100 | 18 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LAB's Valuation (34) in the Medical Specialties industry is somewhat better than the same rating for BLFS (99). This means that LAB’s stock grew somewhat faster than BLFS’s over the last 12 months.
BLFS's Profit vs Risk Rating (91) in the Medical Specialties industry is in the same range as LAB (100). This means that BLFS’s stock grew similarly to LAB’s over the last 12 months.
BLFS's SMR Rating (92) in the Medical Specialties industry is in the same range as LAB (96). This means that BLFS’s stock grew similarly to LAB’s over the last 12 months.
BLFS's Price Growth Rating (46) in the Medical Specialties industry is in the same range as LAB (60). This means that BLFS’s stock grew similarly to LAB’s over the last 12 months.
BLFS's P/E Growth Rating (13) in the Medical Specialties industry is significantly better than the same rating for LAB (100). This means that BLFS’s stock grew significantly faster than LAB’s over the last 12 months.
| BLFS | LAB | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | N/A |
| Stochastic ODDS (%) | 1 day ago 83% | 1 day ago 82% |
| Momentum ODDS (%) | 1 day ago 82% | 1 day ago 85% |
| MACD ODDS (%) | 1 day ago 78% | 1 day ago 86% |
| TrendWeek ODDS (%) | 1 day ago 86% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 79% | 1 day ago 87% |
| Advances ODDS (%) | 3 days ago 77% | 18 days ago 81% |
| Declines ODDS (%) | 8 days ago 85% | 3 days ago 88% |
| BollingerBands ODDS (%) | 1 day ago 78% | N/A |
| Aroon ODDS (%) | 1 day ago 81% | 1 day ago 90% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| PLGAX | 16.27 | 0.10 | +0.62% |
| Principal LargeCap Growth I A | |||
| LAVFX | 16.32 | 0.03 | +0.18% |
| Lord Abbett Fundamental Equity F | |||
| SMSAX | 10.02 | 0.01 | +0.10% |
| SEI Multi Strategy Alternatives F (SIMT) | |||
| OASGX | 12.12 | -0.03 | -0.25% |
| Optimum Small-Mid Cap Growth A | |||
| GDIIX | 22.89 | -0.13 | -0.56% |
| Genter Dividend Income | |||
BLFS and
Correlation & Price change
A.I.dvisor indicates that over the last year, BLFS has been loosely correlated with RGEN. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if BLFS jumps, then RGEN could also see price increases.
| Ticker / NAME | Correlation To BLFS | 1D Price Change % | ||
|---|---|---|---|---|
| BLFS | 100% | -1.18% | ||
| RGEN - BLFS | 59% Loosely correlated | -3.74% | ||
| A - BLFS | 51% Loosely correlated | +0.01% | ||
| RVTY - BLFS | 50% Loosely correlated | -5.13% | ||
| TWST - BLFS | 49% Loosely correlated | -0.91% | ||
| AZTA - BLFS | 49% Loosely correlated | -2.62% | ||
More | ||||
LAB and
Correlation & Price change
A.I.dvisor indicates that over the last year, LAB has been loosely correlated with CLPT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LAB jumps, then CLPT could also see price increases.
| Ticker / NAME | Correlation To LAB | 1D Price Change % | ||
|---|---|---|---|---|
| LAB | 100% | +4.03% | ||
| CLPT - LAB | 45% Loosely correlated | -1.73% | ||
| TMCI - LAB | 44% Loosely correlated | +1.12% | ||
| CERS - LAB | 44% Loosely correlated | +3.15% | ||
| ENOV - LAB | 44% Loosely correlated | -0.58% | ||
| BLFS - LAB | 42% Loosely correlated | -1.18% | ||
More | ||||